Automated surface-bound oligoseed DNA amplification enabling advanced therapies and diagnostics

自动表面结合寡种子 DNA 扩增可实现先进的治疗和诊断

• 批准号: 10056281
• 金额: $ 46.35万
• 依托单位: NUNABIO LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10056281
• 关键词: Automated; surface; bound; oligoseed; DNA

Synthetic DNA is a mainstream component for wide-ranging established and emerging industries including cell and gene therapies and molecular diagnostics. The global DNA synthesis market is forecast to reach £3.4bn by 2025, with demand reaching hundreds of kilograms in coming years and vastly outstripping supply. Solid phase phosphoramidite chemistry, the mainstay DNA production method over the past 40 years, suffers from over-dependence on hazardous chemicals, limited accuracy and length, manufacturing delays, expensive shipping, and low yield/quality. High DNA yields largely rely on manufacturing-level scale-up by cloning via plasmid into bacteria, which poses safety concerns and is a costly manufacturing bottleneck. The UK Government Life Sciences Strategy prioritises an escalation in molecular therapeutics and advanced diagnostics development and manufacture, and to build resilience against future pandemics. This will depend on new tools for versatile, low-cost, high yield oligonucleotide synthesis. In the project, Nunabio will apply their multi-patented technology to forge a new improved means of DNA synthesis that will reduce manufacture and shipping delays, increase workflow autonomy and control, reduce solvent usage and contamination, and produce more ready-to-use material, faster and at lower cost. The outputs of the project will help save £583Mn in future industry costs and remove 4.4Mn litres of harmful phosphoramidite synthesis reagents from industrial use by 2029\.

合成DNA是广泛的成熟和新兴行业的主流组成部分，包括细胞和基因治疗以及分子诊断。全球DNA合成市场预计到2025年将达到34亿英镑，未来几年需求将达到数百公斤，远远超过供应。固相亚磷酰胺化学是过去40年来主要的DNA生产方法，其存在过度依赖危险化学品、有限的准确性和长度、制造延迟、昂贵的运输和低产量/质量的问题。高DNA产量在很大程度上依赖于通过质粒克隆到细菌中的制造级规模扩大，这带来了安全问题，并且是昂贵的制造瓶颈。英国政府生命科学战略优先考虑分子疗法和先进诊断技术的开发和制造，并建立抵御未来流行病的能力。这将取决于用于多功能、低成本、高产量寡核苷酸合成的新工具。在该项目中，Nunabio将应用他们的多项专利技术来打造一种新的改进的DNA合成方法，这将减少制造和运输延迟，增加工作流程的自主性和控制，减少溶剂的使用和污染，并以更快的速度和更低的成本生产更多的即用型材料。该项目的产出将有助于在未来的行业成本中节省5.83亿英镑，并在2029年之前从工业用途中去除440万升有害的亚磷酰胺合成试剂。